New immunotherapy combo aims to stop liver cancer return after surgery
NCT ID NCT07658105
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug for up to 6 months or be monitored closely. The main goal is to see how many remain cancer-free after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eparlitozoviril (a dual immunotherapy drug targeting PD-1 and CTLA-4)
- What this could lead to
- If successful, this could point toward a new standard treatment to lower the chance of liver cancer returning after surgery in high-risk patients.
- What could go wrong
- This is a small, early-phase study (60 people) at a single center, so results may not apply broadly. Immunotherapy can cause serious side effects, and the drug may not improve outcomes compared to active surveillance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink liver tumors?
- Ancient herbal mix could boost liver health in advanced cancer
- Double immune attack: new drug combo takes on advanced liver cancer
- Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
- Radiation and drug combo shows promise for tough liver cancers
- New triple therapy aims to stop liver cancer from coming back